Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Massimo Sandrini is active.

Publication


Featured researches published by Massimo Sandrini.


American Journal of Kidney Diseases | 1999

Familial clustering of IgA nephropathy: Further evidence in an Italian population

Francesco Scolari; A. Amoroso; Silvana Savoldi; Gina Mazzola; Elisabetta Prati; Brunella Valzorio; Battista Fabio Viola; Bossini Nicola; Ezio Movilli; Massimo Sandrini; Maurizio Campanini; R. Maiorca

Several lines of evidence suggest that genetic factors have an important role in the pathogenesis of immunoglobulin A (IgA) nephropathy. We report the prevalence of familial IgA nephropathy in a referral center in northern Italy and present the data on HLA genotypes in the families identified. Twenty-six of 185 patients (14%) with IgA nephropathy investigated in Brescia, Italy, were related to at least one other patient with the disease. Restriction fragment length polymorphism (RFLP) analysis of HLA-DR beta and HLA-DQ alpha and beta genes, as well as polymerase chain reaction-based oligonucleotide typing, was performed in family members. The 26 patients with IgA nephropathy belonged to 10 families. Familial relationships between the patients varied greatly, ranging from parent-child to sib-pair to more distant familial relationships. No common nephrotoxic factor was identified in the families. The intervals separating the apparent onset of disease in relatives with IgA nephropathy varied from 8 months to 13 years. In patients with a family history of IgA nephropathy, there was an increased incidence of HLA-DRB1*08 compared with those with sporadic IgA nephropathy. The study shows that a significant number of the patients with IgA nephropathy followed up in Brescia had a family history of disease. The fact that the Italian population, an ethnic group not previously examined, also presents an increased familial susceptibility to IgA nephropathy suggests that familial predisposition is a very common finding for IgA nephropathy. Thus, clinicians should become aware that IgA nephropathy may aggregate within families in a substantial number of cases. In addition, this subgroup of patients with IgA nephropathy offers an ideal opportunity to elucidate the molecular genetics of this disease.


American Journal of Kidney Diseases | 1996

A prospective comparison of bicarbonate dialysis, hemodiafiltration, and acetate-free biofiltration in the elderly

Ezio Movilli; Corrado Camerini; Husni Zein; Girolamo D'Avolio; Massimo Sandrini; Achille Strada; R. Maiorca

Hemodiafiltration (HDF) and more recently acetate-free biofiltration (AFB) have shown good blood purification and cardiovascular stability in young and middle-aged hemodialysis patients. It is not clear if this is also valid for elderly patients. Twelve patients aged more than 70 years (mean age +/- SD, 76 +/- 4 years) on regular dialysis for at least 5 months were treated with bicarbonate dialysis (BD), HDF, or AFB in a randomized sequence and prospectively followed for 6 months (72 dialysis sessions/patient) for each procedure. The dialysis solution (containing bicarbonate), blood flow rate, and dialysate flow rate were the same with all the methods. During HDF and AFB solutions containing bicarbonate at a concentration of 27 to 30 mEq/L and 145 mEq/L, respectively, were infused postdilution at a rate of 66 +/- 7 mL/min and 2.81 +/- 0.12 L/hr, respectively. During the period of observation we evaluated the number of intradialytic hypotensions, the episodes of nausea, vomiting, headache (dialysis intolerance), body weight, the interdialysis weight gain, the duration of the dialysis session, the number of hospitalizations/patient, and the length of hospitalization/patient. At the end of each observation period we determined: Kt/V, protein catabolic rate, acid base balance, serum creatinine, serum calcium, serum phosphorus, alkaline phosphatases, and serum intact parathyroid hormone. After the switch from BD to either HDF or AFB, the results have shown a significant reduction of dialysis hypotension episodes (18 percent on BD, 14 percent on HDF, and 13 percent on AFB; BD v HDF, P = 0.001; BD v AFB, P = 0.0001; and HDF v AFB, P = NS) and of dialysis intolerance (3.3 percent on BD, 1.3 percent on HDF, and 1.1 percent on AFB; BD v HDF, P = 0.021; BD v AFB, P = 0.019; and HDF v AFB, P = NS). Kt/V improved significantly after the switch from BD to either HDF or AFB (1.17 +/- 0.06 on BD, 1.32 +/- 0.12 on HDF, and 1.32 +/- 0.13 on AFB; BD v HDF, P = 0.021; BD v AFB, P = 0.003; HDF v AFB, P = NS). Protein catabolic rate also improved in HDF and AFB compared with BD (0.90 +/- 0.12 on BD, 1.03 +/- 0.15 on HDF, and 1.04 +/- 0.14 on AFB; BD v HDF, P = 0.001; BD v AFB, P = 0.009; and HDF v AFB, P = NS). AFB showed a better correction of acidosis compared either with BD or HDF (serum bicarbonate, 20.3 +/- 1.1 mEq/L on BD, 20.8 +/- 2.2 mEqL on HDF, and 22.2 +/- 2.4 mEq/L on AFB; BD v HDF, P = NS; BD v AFB, P = 0.01; and HDF v AFB, P = 0.030). The other parameters observed did not differ. In conclusion HDF and AFB show a better dialysis efficiency and a better hemodynamic tolerance compared with BD. This fact is associated with an improvement in protein intake as assessed by kinetic criteria. Acetate-free biofiltration has the further advantage of a better control of the acid-base balance compared with BD and HDF. HDF and AFB are useful dialytic options to traditional BD hemodialysis even in patients older than 70 years.


American Journal of Cardiology | 1991

Improvement in exercise capacity after correction of anemia in patients with end-stage renal failure

Marco Metra; Giuseppe Cannella; Giovanni La Canna; Tiziana Guaini; Massimo Sandrini; Mario Gaggiotti; Ezio Movilli; Livio Dei Cas

Changes in exercise tolerance occurring after correction of anemia with recombinant human erythropoietin in a group of patients with end-stage renal failure were evaluated. Ten patients, aged 29 +/- 11 years, on chronic hemodialysis treatment, with no associated diseases, were evaluated by cardiopulmonary bicycle exercise testing and M-mode, 2-dimensional and pulsed doppler echocardiography before and after anemia correction. After 1 and 3 months of therapy, hemoglobin plasma levels increased from 5.9 +/- 1.2 to 7.7 +/- 1.3 and 9.9 +/- 1.4 g/dl, with a concomitant increase in peak oxygen consumption (VO2) from 21.4 +/- 4.3 to 24.4 +/- 4.3 and 26.6 +/- 4.6 ml/kg/min and of VO2 at the ventilatory threshold from 15.0 +/- 3.7 to 17.3 +/- 3.7 and 16.8 +/- 3.4 ml/kg/min. After 3 months of therapy, systolic blood pressure significantly decreased both at peak exercise (159 +/- 35 to 134 +/- 22 mm Hg) and ventilatory threshold (140 +/- 27 to 123 +/- 19 mm Hg), whereas cardiac index at rest decreased from 3.3 +/- 0.7 to 2.8 +/- 0.5 liters/min/m2 and heart rate from 77 +/- 12 to 70 +/- 10 beats/min. However, no significant relation was found between hemoglobin plasma levels and peak VO2, whereas a significant relation was found between hemoglobin concentration and cardiac index at rest.


American journal of noninvasive cardiology | 1990

Effects of intravascular volume loading and unloading on atrial sizes and left ventricular function in dialyzed uremic man

Deodato Assanelli; Giuseppe Cannella; Ugo Paolo Guerra; Silvio Cuminetti; Mario Gaggiotti; Massimo Sandrini

To evaluate the extent to which opposing changes in circulating blood volume might influence atrial dimensions and left ventricular performance, 11 dialyzed uremic patients with normal baseline left ventricular contractile indices were studied immediately before and after body fluid removal by ultrafiltration and again when they had returned to their original fluid-overloaded state (48 h later). Atrial and left ventricular dimensions were measured by two-dimensional echocardiography, and total blood volume by 131 I-labelled serum albumin, on every occasion


Journal of Nephrology | 2018

Nutritional treatment of advanced CKD: twenty consensus statements

Adamasco Cupisti; Giuliano Brunori; Biagio Di Iorio; Claudia D’Alessandro; Franca Pasticci; Carmela Cosola; Vincenzo Bellizzi; Piergiorgio Bolasco; Alessandro Capitanini; Anna Laura Fantuzzi; Annalisa Gennari; Giorgina Barbara Piccoli; Giuseppe Quintaliani; Mario Salomone; Massimo Sandrini; Domenico Santoro; Patrizia Babini; Enrico Fiaccadori; Giovanni Gambaro; Giacomo Garibotto; Mariacristina Gregorini; Marcora Mandreoli; Roberto Minutolo; Giovanni Cancarini; Giuseppe Conte; Francesco Locatelli; Loreto Gesualdo

The Italian nephrology has a long tradition and experience in the field of dietetic-nutritional therapy (DNT), which is an important component in the conservative management of the patient suffering from a chronic kidney disease, which precedes and integrates the pharmacological therapies. The objectives of DNT include the maintenance of an optimal nutritional status, the prevention and/or correction of signs, symptoms and complications of chronic renal failure and, possibly, the delay in starting of dialysis. The DNT includes modulation of protein intake, adequacy of caloric intake, control of sodium and potassium intake, and reduction of phosphorus intake. For all dietary-nutritional therapies, and in particular those aimed at the patient with chronic renal failure, the problem of patient adherence to the dietetic-nutritional scheme is a key element for the success and safety of the DNT and it can be favored by an interdisciplinary and multi-professional approach of information, education, dietary prescription and follow-up. This consensus document, which defines twenty essential points of the nutritional approach to patients with advanced chronic renal failure, has been written, discussed and shared by the Italian nephrologists together with representatives of dietitians (ANDID) and patients (ANED).


Journal of Nephrology | 2013

Peritoneal ultrafiltration in patients with advanced decompensated heart failure

Iadarola Gm; P Lusardi; La Milia; Amici G; Stefano Santarelli; Virga G; Carlo Basile; Silvio Bertoli; R Bonofiglio; G Del Rosso; M. Feriani; Emilio Galli; Maurizio Gallieni; Giovanni Gambaro; Massimo Sandrini; S Sisca; Giovanni Cancarini

The aim of the Best Practice guidelines on peritoneal ultrafiltration (UF) in patients with treatment-resistant advanced decompensated heart failure (TR-AHDF) is to achieve a common approach to the management of decompensated heart failure in those situations in which all conventional treatment options have been unsuccessful, and to stimulate a closer cooperation between nephrologists and cardiologists. The standardization of the case series of different centers would allow a better definition of the results published in the literature, without which they are nothing more than anecdotes. TR-AHDF is characterized by the persistence of severe symptoms even when all possible pharmacological and surgical options have been exhausted. These patients are often treated with methods that allow extracorporeal UF - slow continuous ultrafiltration (SCUF) and continuous renal replacement therapy (CRRT) - which have to be performed in hospital facilities. Peritoneal ultrafiltration (PUF) can be considered a treatment option in patients with TR-AHDF when, despite the fact that all treatment options have been used, patients meet the following criteria: • stage D decompensated heart failure (ACC/AHA classification); • INTERMACS level 4 decompensated heart failure; • INTERMACS frequent flyer profile; • chronic renal failure (estimated glomerular filtration rate <50 ml/min per 1.73 m2: KDOQI classification stage 3 chronic kidney disease); • no obvious contraindications to peritoneal UF. PUF treatment modes are derived from the treatment regimens proposed by various authors to obtain systemic UF in patients with severe decompensated heart failure, using manual and automated incremental peritoneal dialysis involving various glucose concentrations in addition to the single icodextrin exchange. These guidelines also identify a minimum set of tests and procedures for the follow-up phase, to be supplemented, according to the centers resources and policy, with other tests that are less routine or more complex also from a logistic/organizational standpoint, emphasizing the need for the patients clinical and treatment program to involve both the nephrologist and the cardiologist. The pathophysiological aspects of a deterioration in kidney function in patients with decompensated heart failure are also considered, and the results of PUF in patients with decompensated heart failure reported in the various case series are reviewed.


Journal of Nephrology | 2014

Erratum to: Dialysis adequacy in peritoneal dialysis

Giovambattista Virga; Vincenzo La Milia; Giovanni Cancarini; Massimo Sandrini

On page S116, in the text of paragraph 4.4, first column, and in the title of Table XI, ‘‘required to remove approximately 100 mEq/day’’ is correct, instead of ‘‘required to remove approximately 120 mEq/day’’. The original publication (J Nephrol. 2013 Nov–Dec;26 Suppl 21:96–119) can be found at: http://www.sin-italy.org/web/eventi/SIN/index_rivista.cfm? List=WsTitoloEvento,WsIdEvento&c1=10&c2=00187


Giornale di Tecniche Nefrologiche e Dialitiche | 2014

Does penetration of peritoneal dialysis have a cutoff? How to overcome it?

Massimo Sandrini; Valerio Vizzardi; Luigi Manili; Giovanni Cancarini

At the dialysis center of Brescia, with experience in peritoneal dialysis (PD) of more than 30 years, the incidence of PD is 35%. Despite this, the prevalence of PD has an apparently fixed cutoff at about 80 patients. This short paper synthesizes some possible solutions to increase penetration of PD.


Nephrology Dialysis Transplantation | 1991

Reversal of Left Ventricular Hypertrophy Following Recombinant Human Erythropoietin Treatment of Anaemic Dialysed Uraemic Patients

Giuseppe Cannella; G. La Canna; Massimo Sandrini; Mario Gaggiotti; G. Nordio; Ezio Movilli; S. Mombelloni; O. Visioli; R. Maiorca


Nephrology Dialysis Transplantation | 2001

Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients

Ezio Movilli; Giovanni Cancarini; Roberta Zani; Corrado Camerini; Massimo Sandrini; R. Maiorca

Collaboration


Dive into the Massimo Sandrini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giovanni Gambaro

Catholic University of the Sacred Heart

View shared research outputs
Researchain Logo
Decentralizing Knowledge